US7892750.pdf (1.1 MB)
Cathepsin E as a marker of colon cancer
standard
posted on 2016-06-07, 00:00 authored by Francis J. Castellino, Mary Prorok, Rudolph M. NavariElevated levels of cathepsin E (catE) are demonstrated to be diagnostic of intestinal forms of cancer, such as colorectal cancer. Elevated levels of cathepsin E (catE, monomeric forms) are demonstrated to be detectable in the urine of animals having colorectal cancer, and a diagnostic/screening method for identifying and/or detecting colorectal in an animal from a urine sample is provided. Specific tissue immunohistochemcial staining for catE (monomeric forms) in dysplastic tissue is also disclosed, and is shown to correlate with the level of dysplastic lesion severity. Hence, a method for determining and identifying dysplastic lesion severity is provided. Cathepsin E mRNA transcription and expression levels are also demonstrated to be upregulated in dysplastic tissue, relative to non-dysplastic tissue. Hence, a method for transcriptionally profiling an animal to monitor the progression of colorectal disease is provided.
History
Patent Number
US 7892750 B2Other Application
11/312,780Inventor
Rudolph M. Navari Mary Prorok Francis J. CastellinoInventor from Local Institution
Rudolph M. Navari Francis J. Castellino Mary ProrokAssignee
University of Notre Dame Du LacDate Modified
2016-06-07Language
- English
Claims
12Publisher
United States Patent and Trademark OfficeCooperative Patent Classification Codes
G01N 33/573 (20130101); G01N 33/57419 (20130101); G01N 2333/948 (20130101)Contributor
Rudolph M. Navari|Francis J. Castellino|Mary ProrokInternational Patent Classification Codes
G01N 33/53 (20060101)US Patent Classification Codes
435/7.1; 530/350; 530/387.1;Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC